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Abstract 10 
Ochratoxin A (OTA) is a widespread and abundant natural carcinogenic mycotoxin produced 11 
by several species of Aspergillus and Penicillium fungi. Due to the ubiquitous presence of 12 
these fungi in food and potential risk for human health, a rapid and sensitive in vitro detection 13 
assay is required. Analytical methods for OTA detection/identification are generally based on 14 
liquid–liquid extraction, clean-up using an immunoaffinity column (IAC), and identification 15 
by reversed-phase high pressure liquid chromatography with fluorescence detection (HPLC-16 
FLD). However, IACs are costly and have a short lifespan. Therefore, an interesting approach 17 
would appear to be the design and chemical synthesis of a mimotope peptide simulating 18 
mycotoxin-specific antibodies. We have developed a promising alternative method that is 19 
based on the use of peptides which are able to bind to specific chemical functions and/or 20 
molecular structures. Accordingly, a number of peptides (derived from the structures of major 21 
redox proteins) were selected and produced by chemical solid phase syntheses. The ability of 22 
such peptides to bind to ochratoxin A was evaluated by HPLC. The peptide NF04 23 
(structurally derived from an oxidoreductase enzyme), which was found to be the sole 24 
potently reactive compound among tested molecules, was further evaluated in a peptide-based 25 
enzyme-linked immunosorbent assay (peptide-based ELISA), thus confirming its specific 26 
interaction with ochratoxin A. 27 
Keywords: peptide binding, peptide-based assay, ochratoxin A, mycotoxin 28 
 29 
1. Introduction 30 
Ochratoxin A, also referred to as OTA, is a coumarinic mycotoxin produced by several fungi 31 
species from Aspergillus (e.g., A. ochraceus) and Penicillium (e.g., P. verrucosum) genera 32 
under different environmental conditions (Scott et al., 1997; Brera et al., 2008). It is a 33 
mycotoxin that has been identified as a contaminant in grains, cereals, beans, coffee, dried 34 
fruits and wine (Zimmerli et al., 1995, Varga et al., 2006; Blessa et al., 2006). OTA is known 35 
to have nephrotoxic, immunotoxic, teratogenic and carcinogenic effects (O’Brien et al., 2005, 36 
Pfohl-Leszkowicz et al., 2002, Smith et al., 1995). Wine contamination by OTA has been 37 
described and largely reviewed by several authors (Varga et al., 2006; Blessa et al., 2006). 38 
This beverage is widely consumed and represents a major source of daily OTA intake for the 39 
population (Jorgensen et al., 2005). Thus, regulatory limits for OTA exist in many countries, 40 
especially in Europe where maximum limits for OTA in wine, grape juices and grape 41 
beverages, have been fixed at 2 µg l
−1
 (European Union, 2005, 2010). Nowadays, the most 42 
widely used quality control process relies on an immunoaffinity column (IAC), followed by 43 
reversed-phase high pressure liquid chromatography using fluorescence detection (HPLC-44 
FLD) (Visconti et al., 1999, Aresta et al., 2006). Because this mycotoxin is largely 45 
represented in food, availability of rapid, reliable and sensitive analytical methods for the 46 
detection of OTA is required to protect consumers’ health. Despite the fact that the IAC 47 
procedure is rather simple, sensitive and quite reproducible, IACs are unfortunately too costly, 48 
together with short shelf lives. In the last decade, several groups attempted to develop 49 
appropriate alternative assays to improve rapidity and sensitivity, combined with cost 50 
reduction. Such methods rely on immunoassays, test strips and biosensors. First, a 51 
competitive ELISA kit has been used widely in recent years for the detection of OTA. 52 
ELISAs for ochratoxin content analyses have been reported in barley (Morgan et al., 1983). 53 
The assay sensitivity for detection of OTA in barley samples was circa 5 µg kg
-1
 54 
(Ramakrishna et al., 1990). Angelini et al., (2008) compared performance of four extraction 55 
procedures and three commercial ELISA kits for OTA in grapes. Sometimes, IAC are used to 56 
concentrate OTA. The advantage of using IAC after the extraction procedure was the 57 
excellent detection limit, which was between 0.06 and 0.0075 µg l
-1
. This detection limit 58 
depends on the ELISA kit used. Second, the test strip, also called lateral flow device or 59 
immunochromatographic strip (ICS) test, is based on a membrane loaded with immobilized 60 
antibodies. They are of simple use and give faster results (2 to 15 min). Test strips are semi-61 
quantitative with different visual limits of detection (LOD) in function of the nature of sample 62 
(Krska et al., 2009; Shim et al., 2009). Initially, the LOD was set at ca. 500 µg l
−1
 of OTA 63 
(Cho et al., 2005; Rusanova et al., 2009), whereas, nowadays, the cutoff level dropped down 64 
to 1 µg l
−1
, which corresponds to the lower limit tolerated by the Food and Drugs 65 
Administration. Third, with regard to biosensors, their characteristics depend on the nature of 66 
the bioreceptor and the physical transducer. Antibodies, which show high selectivity and 67 
affinity towards mycotoxins, have been widely used to set up a variety of immunosensors 68 
(e.g. electrochemical, impedimetric or conductimetric immunosensors) against mycotoxins 69 
like OTA (Pietro-Simon et al., 2008; Liu et al., 2009; Alacon et al., 2006; Radi et al., 2008 70 
and 2009). 71 
 The well-known favorable molecular recognition characteristics of an antibody (in 72 
terms of affinity and selectivity) are counterbalanced by the unfavorable use of different 73 
matrix samples or experimental conditions of assay (e.g. denaturation of antibodies in organic 74 
solvents). To overcome these drawbacks, several strategies have been followed such as 75 
development of new synthetic systems that mimic the recognition properties of antibodies. 76 
Indeed, many efforts have been made to substitute OTA antibodies by DNA aptamers (Cruz-77 
Aguado et al., 2008a, 2008b), molecularly imprinted polymers (MIP) (Ali et al., 2010; Yu et 78 
al., 2010) and phage display libraries (Giraudi et al., 2007). The isolation of oligonucleotide 79 
sequences (DNA aptamers) and synthetic receptor(s) (MIP) that recognize this class of target 80 
molecules have some advantages compared to antibodies. They can be generated easily and 81 
are stable at different pH values and/or at high temperatures. Among these approaches, based 82 
on synthetic systems, none of them reach affinity for OTA that is compatible with the 83 
detection limits fixed in wine by the European Commission (2.0 µg l
−1
) or the rest of the 84 
world (1.0 µg l
−1
). The first hexapeptide selected using phage display libraries exhibits an 85 
affinity of ca. 3.4 x 104 M−1 towards OTA (Giraudi et al., 2007). Although moderate, such a 86 
peptide affinity can be potentially increased by some structure-activity relationship studies. 87 
Peptide-based detection assays in general are commercially available and most frequently 88 
used in the biomedical field rather than environmental sciences which is of concern in this 89 
study. For examples, peptides are used in various fields, from diagnosis of HIV infection 90 
(Alcaro et al., 2003; Ravanshad et al., 2006, Gerasimov 2010) to detection of potential 91 
sensitizing compounds (Gerberik et al., 2004). 92 
Apart from the previously described techniques used for OTA quantification, we describe in 93 
this work for the first time a novel approach based on the identification of new peptides (not 94 
based on phage display analyses) which exhibit significant affinities towards OTA. HPLC 95 
was used as an analytical method to select the most potent peptide interacting with OTA in a 96 
binding assay. Identification of such a peptide is important and allowed us to analyze some 97 
red wine samples that were previously supplemented with OTA in a peptide-based enzyme-98 
linked immunosorbent assay (peptide-based ELISA). 99 
2. Material and methods 100 
2.1.  Materials 101 
N -fluorenyl-9-methyloxycarbonyl (Fmoc)-L-amino acids, Fmoc-amide rink resin, and 102 
reagents used for peptide synthesis were obtained from Iris Biotech (Germany). Solvents were 103 
analytical grade products from Carlo-Erba (France). 104 
 105 
2.2.  Chemicals 106 
OTA was obtained from Sigma-Aldrich (France). A solution was prepared in methanol at 1 107 
mg ml
-1
. PEG 8000 (Polyethylene Glycol) and PVPP were obtained from Promega (France). 108 
Luminol was obtained from Pierce (France). 109 
 110 
2.3.  Solid-Phase Peptide Synthesis 111 
The peptides (NF01, NF02, NF03, NF04, Chim1, pep01 and pep02) were produced by 112 
chemical synthesis using a peptide synthesizer (Model 433A, Applied Biosystems Inc.). The 113 
amino acid sequence of the most reactive peptide, i.e. NFO4, is provided in Fig. 2B. All 114 
peptide sequences are described in European patent n° 12305269.8 (deposited by Tournoux 115 
Biotech on March 5
th
 2012). Peptide chains were assembled stepwise on 0.25 mmol of Fmoc-116 
amide resin (1% cross-linked; 0.65 mmol of amino group/g) using 1 mmol of N -(9-117 
fluorenyl)methyloxycarbonyl (Fmoc) L-amino acid derivatives. Side chain-protecting groups 118 
for trifunctional residues were: trityl for cysteine, and asparagine; t-butyl for tyrosine, 119 
glutamate and aspartate; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for arginine; and 120 
t-butyloxycarbonyl for lysine. N -amino groups were deprotected by successively treating 121 
with 18 and 20% (v/v) piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. After 122 
three washes with N-methylpyrrolidone, the Fmoc-amino acid derivatives were coupled (20 123 
min) as their hydroxybenzotriazole active esters in N-methylpyrrolidone (4-fold excess). After 124 
peptides were assembled, and removal of N-terminal Fmoc groups, the peptide resins (ca. 1.5 125 
g) were treated under stirring for 2.5 h at 25°C with mixtures of trifluoroacetic 126 
acid/H2O/thioanisole/ethanedithiol (73:11:11:5, v/v) in the presence of crystalline phenol (2.1 127 
g) in final volumes of 30 ml per gram of peptide resins. The peptide mixtures were filtered, 128 
precipitated and washed twice with cold diethyloxide. The crude peptides were pelleted by 129 
centrifugation (3,200  g; 10 min). They were then dissolved in H2O and freeze dried. The 130 
crude peptides were purified to homogeneity by reversed-phase high pressure liquid 131 
chromatography (HPLC) (C18 Aquapore ODS, 20 µm, 250  10 mm; PerkinElmer Life 132 
Sciences) by means of a 60-min linear gradient of 0.08% (v/v) trifluoroacetic acid/H2O 133 
(buffer A) with 0 to 40% of 0.1% (v/v) trifluoroacetic acid/acetonitrile (buffer B), at a flow 134 
rate of 4 ml/min (  = 230 nm). The purity and identity of each peptide were assessed by: (i) 135 
analytical C18 reversed-phase HPLC (C18 Lichrospher 5 µm, 4  200 mm; Merck) using a 60 136 
min linear gradient of buffer A with 0-60% of buffer B, at a flow rate of 1 ml/min; and (ii) 137 
molecular mass determination by matrix-assisted laser desorption ionization-time of flight 138 
(MALDI-TOF) spectrometry (Voyager DE-RP, Perceptive Biosystems Inc.). 139 
 140 
2.4.  HPLC-based peptide binding assays 141 
Eighty microlitres of a peptide (NF01, NF02, NF03, NF04, Chim1, pep01 or pep02) at a 142 
concentration of 1.25 mM in 0.1 M Tris-HCl buffer, pH 8.3, were tested with 10 µl of OTA 143 
solution at 0.1 M in acetonitrile, supplemented with 70 µl of 0.1 M Tris-HCl buffer (pH 8.3) 144 
and 40 µl acetonitrile. The mixture of peptide and OTA was incubated for 4 h in the dark, at a 145 
temperature of 30°C. The reaction medium (200 µl) was then analyzed by C18 reversed-phase 146 
HPLC (C18 Aquapore ODS, 20 µm, 250  10 mm; PerkinElmer Life Sciences) by means of a 147 
40-min linear gradient of 0.08% (v/v) trifluoroacetic acid/H2O (buffer A) with 0 to 60% of 148 
0.1% (v/v) trifluoroacetic acid/acetonitrile (buffer B), at a flow rate of 1 ml/min (  = 230 nm). 149 
Peptide reactivity with OTA was finally assessed by comparing the peak areas corresponding 150 
to free peptide (unreactive peptide) between the test sample of peptide/OTA, and a reference 151 
sample of peptide alone (without OTA). It is worth mentioning that results obtained with the 152 
reference samples (peptides alone) are similar to those obtained with peptides incubated with 153 
irrelevant, unreactive products (data not shown). The identity of free peptides and 154 
peptide/OTA complexes was verified by MALDI-TOF mass spectrometry. Binding assays 155 
were performed in triplicate. 156 
 157 
2.5.  Peptide-based competitive enzyme-linked immunosorbent assay (peptide-based 158 
competitive ELISA) 159 
Polystyrene white microtiter plate wells (Maxisorb LumiNunc, Thermoscientific, USA), 160 
coated with the synthetic peptide NFO4 at an optimized concentration of 5 μg/100 μl in 161 
carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, 0.2 g/L NaN3, pH 9.6) were incubated at 162 
37°C for 3 h. Non-specific binding sites of the peptide-coated wells were blocked with 5% 163 
nonfat dry milk in PBS containing 0.1% Triton X-100 (milk buffer) at room temperature (RT) 164 
for 3 h before performing the test. Fifty µl of OTA-HRP (horseradish peroxidase) were added 165 
in each well combined with 50 µl of phosphate buffer saline or red wine sample supplemented 166 
with unlabeled OTA. The reaction was left for 30 min at RT. After washing unbound OTA, 167 
40 μl of luminol (Pierce, France) substrate was added in each well. After 5 min of enzymatic 168 
reaction, light emission signals ( max = 425 nm) were analyzed using an automated 169 
microplate luminescence reader (Berthold, France). Light intensity was expressed in Relative 170 
Luminescent Unit (RLU). The result obtained is inversely proportional to the concentration of 171 
unlabeled OTA. During each test, nonspecific binding (negative control) was determined by 172 
using an incubation mixture (OTA-HRP) in which the peptide NFO4 was replaced by 100 μL 173 
of carbonate buffer. All the samples were tested in triplicate and the mean of the peak light 174 
emission was taken as the final light signal value. 175 
 176 
2.6.  Calculation methods 177 
In order to evaluate the peptide-based competitive assay, a calibration curve was set up by 178 
using solutions containing well-defined concentrations of OTA. In that direct competitive 179 
peptide-based ELISA, results are expressed in B/Bo dose logarithmic function. B and Bo 180 
represent the enzyme-bound activity measured in the presence or absence of competitor, 181 
respectively. The standard curve was traced by plotting standard concentrations on x-axis 182 
(logarithmic scale) and percentage of maximal binding (express in % of B/B0) on y-axis (B / 183 
Bo = f (log [OTA])). The binding values are obtained by dividing the light intensity of each 184 
testing well B (the luminescence measured when OTA-HRP and unlabeled OTA are in 185 
competition with NFO4 peptide) by the light intensity of the positive control well B0 186 
(maximum luminescence obtained with OTA-HRP). This method allows the comparison of 187 
results between assays performed on different plates or different days. While the absolute 188 
light emission may differ from plate to plate or day to day, the percentage of B/Bo values 189 
should be reasonably consistent from one plate to the next. All measurements were made in 190 
triplicate. The minimum detectable concentration (MDC) was taken as the concentration of 191 
competitor (unlabeled OTA) inducing a significant decrease in Bo. The effect of complex 192 
matrix was established by testing a red wine sample. 193 
 194 
2.7.  Specificity measurements 195 
The specificity of the peptide immunoassay described previously was controlled by testing its 196 
capacity to detect or not ochratoxin B (OTB), another mycotoxin structurally related to OTA. 197 
Results are expressed as percentage of cross-reactivity, defined as the ratio (%) of the 198 
concentration of OTA and OTB compounds at 50% B/Bo. Cross-reactivity measurement was 199 
carried out in triplicates. 200 
 201 
2.8.  Preparation of matrix samples for peptide EIA: wine pretreatment  202 
In order to study matrix-associated effects, a study with red wine was carried out. A sample of 203 
10 ml of wine supplemented (or not) with OTA (1.25 to 15 µg l
-1
) has been diluted with 10 204 
mL of PEG8000 1% - NaHCO3 5% solution. This mixture has been incubated for 30 min at 205 
RT on a rocker. Afterwards, it was centrifuged at 8000 rpm for 15 min. The whole sample is 206 
filtered before analysis with the peptide-based enzyme-linked immunosorbent assay.  207 
 208 
3. Results and discussion  209 
3.1. Rationale of the study 210 
The mycotoxin OTA from Aspergillus (e.g., A. ochraceus) and Penicillium (e.g., P. 211 
verrucosum) genera is a complex organic compound that contains several functional groups, 212 
including carbonyl (ester: R
1
COOR
2
, and amide: R
1
CONHR
2
R
3
) and phenol (i.e -OH) 213 
moieties (Fig. 1A). We designed and chemically produce a number of peptides (European 214 
patent deposit n°12305269.8, 2012) derived from specific regions of redox proteins (e.g. 215 
oxidoreductase) and ABC transporters that potently react -in an HPLC-based binding assay- 216 
with more or less complex molecules containing such functional group(s), i.e carbonyl and/or 217 
phenol (Table 1a and b). The carbonyl group (i.e C=O) is shared by several types of organic 218 
compounds and comprises ketone, aldehyde, ester, amide, carboxylic acid, acid anhydride, 219 
enone and acyl halide. We evaluated whether or not these selected peptides would interact 220 
with OTA. As shown in Table 2, three peptides (NFO2, NFO3 and NFO4), with related 221 
molecular structures (up to 83% sequence identity) derived from human NADH-FMN 222 
oxidoreductase significantly interacted with the mycotoxin. The experimental molecular 223 
masses, as determined by MALDI-TOF mass spectrometry, were (M+H)
+
: 1793.17 Da 224 
(NFO2), 1722.15 Da (NFO3) and 1598.99 Da (NFO4), consistent with their calculated 225 
molecular structures. Among reactive peptides, NFO4 was the most potent compound, with 226 
70% binding to OTA in our experimental conditions of binding assay. NFO4 amino acid 227 
sequence is provided in Fig. 1B. Fig. 2A shows binding assays with representative HPLC 228 
profiles of three reaction media corresponding to NF04 incubated for 4 h at 30°C with lactic 229 
acid as negative control (left panel), hydroquinone as positive control (center panel) and OTA 230 
(right panel). Interaction of NFO4 with hydroquinone or OTA is highlighted by the 231 
disappearance (hydroquinone) or decrease (OTA) of peak area corresponding to free-unbound 232 
NFO4. HPLC profiles showing binding of other peptides to OTA are also shown for 233 
comparison (Fig. 2B). For example, NFO1 and Chim1 showed binding inferior to 10%, while 234 
NFO2 showed binding at 35%. 235 
Using NFO4, the threshold of OTA detection was found to be in the same concentration range 236 
as the one requested by the European commission regulation (2 µg l
-1
 OTA). Although the 237 
potency of OTA detection by NFO4 is actually moderate, one can anticipate that optimizing 238 
both NFO4 structure (in a structure-activity relationship study) and the experimental 239 
conditions of binding assay could improve sensitivity of peptide-based detection, and yield to 240 
the desired mycotoxin detection range in wine. Overall, experimental data obtained strongly 241 
suggest that, basically, a peptide-based detection assay of OTA might be a promising 242 
approach. 243 
 244 
3.2.  Peptide-based competitive enzyme-linked immunosorbent assay  245 
Competitive ELISAs are most commonly used to measure various molecules including lipids, 246 
hormones, and small peptides if they are present in high enough concentrations. In this study, 247 
this type of assay is based on the competition between the analyte of interest, OTA, and an 248 
enzyme horseradish peroxidase-conjugated version of the same analyte (referred to as the 249 
tracer, OTA-HRP) for a limited number of specific peptide NFO4 binding sites (Fig. 3). The 250 
concentration of OTA-HRP is held constant in all wells while the concentration of OTA 251 
varies from well-to-well (0 µg l
−1
, 1.25 µg l
−1
, 2 µg l
−1
, 2.5 µg l
−1
, 5 µg l
−1
, 10 µg l
−1
 and 15 252 
µg l
−1
). As a result, the amount of tracer that can bind to the peptide NFO4 will be inversely 253 
proportional to the amount of analyte in the well – the presence of more analyte means less 254 
tracer will be able to bind to the specific peptide. 255 
The standard curves obtained for peptide-based competitive ELISA in PBS are shown (Fig. 256 
4A). The exponential curve fit for the standard OTA in PBS gives a clear graphical 257 
representation of how the competition proceeds. Inhibition starts at 1.25 µg l
-1
 and reaches a 258 
maximum at 10 µg l
-1
. Inhibition is complete which is expected since the tracer is also OTA-259 
based. Half-inhibition occurs at a value of 3.2 µg l
-1
, which should grossly correspond to the 260 
Kd value of NFO4 for OTA. We consider that with this test the LOD for OTA is at 1.25 µg l
-1
 261 
and that differences in OTA concentration can be discriminated between 1.25 and 10 µg l
-1
. 262 
Cross-reactivity measurement of the peptide test was carried out using OTB (Fig. 4A). The 263 
OTB concentration inducing 50% of the maximum possible decrease of the light signal was 264 
8.5 µg l
−1
, indicating that the affinity of NFO4 for OTB is circa 3-fold lower than for OTA. In 265 
addition, free OTB was a worse competitor than OTA for decreasing OTA-HRP signal. 266 
Maximal decrease reached 69% instead of 100% for concentrations above 15 µg l
-1
. At 10 µg 267 
l
-1
, OTA depleted the signal by 89%, whereas OTB reduced it by 47% clearly indicating that 268 
OTA detection was better than OTB with this system. Next, we evaluated whether our system 269 
could detect OTA from red wine samples. The same range of OTA concentrations was added 270 
to red wine samples. The resulting competition curve was compared to that established with 271 
pure OTA or OTB in PBS (Fig. 4A). Wine OTA could nicely be detected by the system, with 272 
a slight reduction in efficacy which can easily be explained by the enhanced number of non 273 
specific compounds co-present in wine samples. Half-inhibition occurred at 5.8 µg l
-1
 and as 274 
for OTA in PBS the inhibition was complete. The LOD for OTA in wine was 2 µg l
−1
 (Fig. 275 
4B), which is only slightly higher than OTA in PBS. These results suggested that the NFO4 276 
peptide can be used for detection of OTA in red wine matrices.  277 
 278 
4. Conclusions 279 
The European Union (EU) has defined regulatory limits for OTA, i.e., 10 µg l
−1
 in dried vine 280 
fruits and instant coffee, 5 µg l
−1
 in cereals and roasted coffee and 2 µg l
−1
 in wine. Here we 281 
present a new strategy for detection of this important mycotoxin in various matrices like red 282 
wine. We have selected small peptides (12 amino acids) allowing specific recognition of 283 
OTA. The peptide named NFO4 was selected in HPLC for its higher affinity for OTA. We 284 
have validated this result by a peptide-based competitive ELISA in phosphatase buffer saline 285 
and in red wine samples. The peptide-based competitive ELISA showed that NFO4 can 286 
discriminate a contamination of 2 µg l
−1
 of OTA in red wine (without preconcentration of the 287 
sample on immunoaffinity column). This preliminary study highlights the possibility of using 288 
small peptides in biosensor systems (e.g. by electrochemical detection). Modifications of 289 
NFO4 peptide sequence may be required in order to further decrease the observed cross-290 
reactivity with OTB which is potentially related to the phenol moiety of OTB. Such a 291 
structure-activity relationship study may increase the LOD to the lower value of 1 µg l
−1
 292 
which is the world limit for OTA in red wineIn any case, these preliminary data are quite 293 
encouraging and strongly suggest that further work on NFO4 will allow the development of a 294 
more sensitive system, either by peptide modification or by OTA preconcentration by an 295 
affinity column.  296 
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Figure captions 369 
 370 
Figure 1: (A) Chemical structure of Ochratoxin A mycotoxin. (B) Amino acid sequence of 371 
NFO4. Single letter code. 372 
 373 
Figure 2 : HPLC-based peptide-based binding assays. (A) Representative HPLC profiles of 374 
three reaction media corresponding to NF04 incubation with lactic acid as negative control 375 
(left panel), hydroquinone as positive control (center panel) and OTA (right panel). Lactic 376 
acid is not detected on the HPLC profile because of lack of absorption at 230 nm. Complexes 377 
between NF04 and compounds are not detected on HPLC profiles. (B) Representative HPLC 378 
profiles of three peptides incubated with OTA: NFO1 (left), NFO2 (middle), and Chim1 379 
(right). Peak peptide depletions according to control without OTA (not shown) are 7% 380 
(NFO1), 35% (NFO2) and 10% (Chim1). 381 
 382 
Figure 3. Principle of competitive immunoassay with conjugated OTA. (A) The plate is 383 
coated with the peptide NFO4. (B) The peptide is then placed in contact with the sample. If 384 
the sample contains the specific OTA, the toxin links to the specific peptide and the detection 385 
element conjugated with the toxin (usually HRP). (C) The amount of HRP-conjugated toxin 386 
that can be fixed is inversely correlated with the amounts of toxin present in the sample. (D) 387 
The non-fixed compounds are rinsed away before adding a developing product.  388 
 389 
Figure 4. (A) Peptide-based competitive ELISA calibration curve. The x-axis represents the 390 
calibrator concentration of mycotoxin (OTA or OTB). B and Bo represent the bound enzyme 391 
activity measured in the presence or absence of competitor, respectively. Data are average ± 392 
standard deviation, and were fitted by decreasing exponential functions y=y0 + a.e
-bx
. Y0 393 
values were <10 for OTA (wine and PBS) and >30 for OTB. (B) Peptide-based competitive 394 
ELISA with OTA in wine. The negative control is the luminescence emitted with OTA-HRP 395 
without NFO4 peptide. Data are the mean of n=3 ± standard deviation.  396 
 397 
 398 
 Table 1a: HPLC-based peptide binding assays. Percentages of peak area depletion are noted. 
‘100’ corresponds to 100% binding of peptide to indicated chemical compound. ‘0’ 
corresponds to a lack of interaction between peptide and organic compound. 
 
Peptides/chemical 
compounds NFO1 NFO2 NFO3 NFO4 Chim1 
Hydroquinone 100 90 100 100 80 
Phtalic anhydride 95 100 100 100 85 
Diphenylcyclopropenone 0 98 100 99 85 
Cinnamic aldehyde 55 35 100 100 90 
Phenylacetaldehyde 80 20 35 100 55 
Lactic acid 0 0 0 0 0 
Okadaic acid 0 0 0 0 0 
Naphtalene 0 0 0 0 0 
 
Table 1b: Chemical structures of organic compounds studied in HPLC-based peptide binding 
assays. 
Name MW Chemical structure References 
Hydroquinone 110.11 
 
Belchik et al., 
2011 
Phtalic anhydride 148.10 
 
Quartier et 
al., 2006 
Diphenylcyclopropenone 206.25 
 
Ryan et al., 
2000 
Cinnamic aldehyde 132.16 
 
Cocchiara et 
al., 2005 
Phenylacetaldehyde 120.15 
 
Chen et al., 
2011 
Lactic acid 90.08 
 
Shen et al., 
2012 
Okadaic acid 805.00 
 
Franchini et 
al., 2010 
Naphtalene 128.17 
 
Girschikofsky 
et al., 2012 
 
 Table 2: Peptide binding assay. Percentages of peak area depletion are noted. ‘100’ 
corresponds to 100 % binding of peptide to organic compound. ‘0’ corresponds to a lack of 
interaction. 
 
Peptides/chemical 
compounds 
NFO1 NFO2 NFO3 NFO4 Chim1 
OTA 7 35 40 70 10 
Hydroquinone** 100 90 100 100 80 
Lactic acid* 0 5 4 7 1 
 
** Positive control ; * Negative control 
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